Keywords
How to Cite
Abstract
Modern Treatment of Chronic Heart Failure This article delves into the contemporary approaches to managing chronic heart failure (CHF), highlighting significant advancements in both medical and non-medical treatments. It covers:
- Pharmacological Therapies: Key drugs such as ACE inhibitors, ARBs, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors, which play crucial roles in improving heart function and patient outcomes.
- Device-Based Therapies: Technologies like Implantable Cardioverter Defibrillators (ICDs) and Cardiac Resynchronization Therapy (CRT) devices that assist in regulating heart rhythm and improving cardiac efficiency.
- Advanced Therapies: The use of Left Ventricular Assist Devices (LVADs) and heart transplantation for patients with severe heart failure, offering life-extending options.
- Lifestyle Modifications: The importance of diet, exercise, patient education, and self-management in controlling symptoms and improving quality of life.
- Emerging Therapies: Innovations in gene therapy, regenerative medicine, and novel pharmacological agents that hold promise for future treatments.
The article underscores the multifaceted nature of CHF treatment, combining established methods with cutting-edge research to enhance patient care and outcomes.
References
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., ... & Westlake, C. (2017). 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. *Journal of the American College of Cardiology*, 70(6), 776-803. doi: 10.1016/j.jacc.2017.04.025
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., ... & PARADIGM-HF Investigators and Committees. (2014). Angiotensin–neprilysin inhibition versus enalapril in heart failure. *New England Journal of Medicine*, 371(11), 993-1004. doi: 10.1056/NEJMoa1409077
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., ... & EMPEROR-Reduced Trial Investigators. (2020). Cardiovascular and renal outcomes with empagliflozin in heart failure. *New England Journal of Medicine*, 383(15), 1413-1424. doi: 10.1056/NEJMoa2022190
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., ... & EMPHASIS-HF Study Group. (2011). Eplerenone in patients with systolic heart failure and mild symptoms. *New England Journal of Medicine*, 364(1), 11-21. doi: 10.1056/NEJMoa1009492
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., ... & Yancy, C. W. (2022). 2022 AHA/ACC/HFSA guideline for the management of heart failure. *Journal of the American College of Cardiology*, 79(17), e263-e421. doi: 10.1016/j.jacc.2021.12.012
Ezekowitz, J. A., O'Meara, E., McDonald, M. A., Abrams, H., Chan, M., Ducharme, A., ... & Moe, G. W. (2017). 2017 Comprehensive update of the Canadian Cardiovascular Society guidelines for the management of heart failure. *Canadian Journal of Cardiology*, 33(11), 1342-1433. doi: 10.1016/j.cjca.2017.08.022
Writing Group Members, Mozaffarian, D., Benjamin, E. J., Go, A. S., Arnett, D. K., Blaha, M. J., ... & Turner, M. B. (2016). Executive summary: heart disease and stroke statistics—2016 update: a report from the American Heart Association. *Circulation*, 133(4), 447-454. doi: 10.1161/CIR.0000000000000350